Advanced, unresectable Pancreatic Cancer (PC) is an extremely aggressive disease. The 5-year survival rate for Pancreatic Cancer is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited.
If you have been diagnosed with PC you may be searching for effective therapies to manage your disease. You oncologist may have told you that chemotherapy regimens such as gemcitabine, according to the first study linked below, often don’t provide long-term survival.
Reading the second study below however will cite how curcumin can enhance the efficacy of gemcitabine. Further, the third study below will make the case for curcumin and omega-3 fatty acids enhancing each other against pancreatic cancer.
Taken together, could these integrative therapies reduce your PC to a size that can be surgically removed aka the Whipple procedure?
Please take a moment to watch the short video below in order to learn more about some of these therapies:
“Advanced, unresectable pancreatic cancer is an extremely aggressive disease. The 5-year survival rate for PC is only less than 5%. Current therapeutic options for patients with locally advanced or metastatic disease are limited. This analysis is a retrospective evaluation of the efficacy and toxicity of gemcitabine regimen as first-line chemotherapy in patients with advanced pancreatic cancer…
Seventeen chemotherapy-naïve patients with advanced or recurred PC were consecutively treated. Gemcitabine was diluted in normal saline and administered intravenously over 1 hour. Gemcitabine 1,000 mg/m2 was administered once weekly for 3 out of every 4 weeks.
The median age of patients was 55 years (range 44–82 years). Based on RECIST criteria, there were 5 cases of stable disease (45%) and 6 cases of progressive disease (55%) among the 11 assessable patients. The median survival time was 189 days (range, 84 to 409 days), the 1-year survival rate was 18% in all 17 patients. Grade 3–4 toxic side effect was leucopenia only (29%) and was easily managed without infection…”
“Using gemcitabine-resistant PDAC cell lines, we found that curcumin sensitized chemoresistant cancer cells by inhibiting the expression of the PRC2 subunit EZH2 and its related lncRNA PVT1. Curcumin was also found to prevent the formation of spheroids, a hallmark of CSCs, and to down-regulate several self-renewal driving genes.”
Overall, this study indicates clinical relevance for combining curcumin with chemotherapy to overcome chemoresistance in PDAC…”
PC BxPC-3 cells were exposed to curcumin, docosahexaenoic acid (DHA), or combinations of both and analyzed for proliferation and apoptosis. Pancreatic tumor xenografts were established by injecting BxPC-3 cells into each flank of nude mice. After the tumors reached a size of approximately 190-200 mm(3), animals were fed diets with or without 2,000 ppm curcumin in 18% corn oil or 15% fish oil + 3% corn oil for 6 more wk before assessing the tumor volume and expression of inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), and p21. A synergistic effect was observed on induction of apoptosis (approximately sixfold) and inhibition of cell proliferation (approximately 70%) when cells were treated with curcumin (5 microM) together with the DHA (25 microM).
APPIP ERROR: amazonproducts[
AccessDeniedAwsUsers|The Access Key Id AKIAJAJ37JVNL7OUU4CA is not enabled for accessing this version of Product Advertising API. Please migrate your credentials as referred here https://webservices.amazon.com/paapi5/documentation/migrating-your-product-advertising-api-account-from-your-aws-account.html.
What is the protocol of curcumin and omega 3 for neuroendocrine tumor of pancreas ( tail region)Reply